








ORIGINAL RESEARCH

High-Sensitivity C-Reactive Protein Is Associated With Heart Failure Hospitalization in Patients With Metabolic Dysfunction-Associated Fatty Liver Disease and Normal Left Ventricular Ejection Fraction Undergoing Coronary Angiography

Xiao-Dong Zhou , MM^{*}; Qin-Fen Chen , MD^{*}; Giovanni Targher , MD; Christopher D. Byrne , MB, BCh; Michael D. Shapiro , MD; Na Tian, MM; Tie Xiao, MM; Ki-Chul Sung , MD; Gregory Y. H. Lip , MD; Ming-Hua Zheng , MD

BACKGROUND: Systemic chronic inflammation plays a role in the pathophysiology of both heart failure with preserved ejection fraction (HFpEF) and metabolic dysfunction-associated fatty liver disease. This study aimed to investigate whether serum hs-CRP (high-sensitivity C-reactive protein) levels were associated with the future risk of heart failure (HF) hospitalization in patients with metabolic dysfunction-associated fatty liver disease and a normal left ventricular ejection fraction.

METHODS AND RESULTS: The study enrolled consecutive individuals with metabolic dysfunction-associated fatty liver disease and normal left ventricular ejection fraction who underwent coronary angiography for suspected coronary heart disease. The study population was subdivided into non-HF, pre-HFpEF, and HFpEF groups at baseline. The study outcome was time to the first hospitalization for HF. In 10 019 middle-aged individuals (mean age, 63.3±10.6 years; 38.5% women), the prevalence rates of HFpEF and pre-HFpEF were 34.2% and 34.5%, with a median serum hs-CRP level of 4.5 mg/L (interquartile range, 1.9–10 mg/L) and 5.0 mg/L (interquartile range, 2.1–10.1 mg/L), respectively. Serum hs-CRP levels were significantly higher in the pre-HFpEF and HFpEF groups than in the non-HF group. HF hospitalizations occurred in 1942 (19.4%) patients over a median of 3.2 years, with rates of 3.7% in non-HF, 20.8% in pre-HFpEF, and 32.1% in HFpEF, respectively. Cox regression analyses showed that patients in the highest hs-CRP quartile had a ~4.5-fold increased risk of being hospitalized for HF compared with those in the lowest hs-CRP quartile (adjusted-hazard ratio, 4.42 [95% CI, 3.72–5.25]).

CONCLUSIONS: There was a high prevalence of baseline pre-HFpEF and HFpEF in patients with metabolic dysfunction-associated fatty liver disease and suspected coronary heart disease. There was an increased risk of HF hospitalization in those with elevated hs-CRP levels.

Key Words: heart failure hospitalization ■ heart failure with preserved ejection fraction ■ high-sensitivity C-reactive protein ■ metabolic dysfunction-associated fatty liver disease ■ metabolic dysfunction-associated steatotic liver disease

Correspondence to: Ming-Hua Zheng, MD, PhD, MAFLD Research Center, Department of Hepatology, the First Affiliated Hospital of Wenzhou Medical University, Wenzhou, China. Email: zhengmh@wmu.edu.cn

*X. D. Zhou and Q. F. Chen are co-first authors.

This article was sent to Amgad Mentias, MD, Associate Editor, for review by expert referees, editorial decision, and final disposition.

Preprint posted on MedRxiv October 07, 2023. doi: <https://doi.org/10.1101/2023.10.06.23296684>.

Supplemental Material is available at <https://www.ahajournals.org/doi/suppl/10.1161/JAHA.123.032997>

For Sources of Funding and Disclosures, see page 9.

© 2024 The Authors. Published on behalf of the American Heart Association, Inc., by Wiley. This is an open access article under the terms of the [Creative Commons Attribution-NonCommercial-NoDerivs](https://creativecommons.org/licenses/by-nc-nd/4.0/) License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non-commercial and no modifications or adaptations are made.

JAHA is available at: www.ahajournals.org/journal/jaha

CLINICAL PERSPECTIVE

What Is New?

- The pathophysiological link between metabolic dysfunction-associated fatty liver disease and the development and progression of heart failure with preserved ejection fraction may be attributable to low-grade chronic inflammation.

What Are the Clinical Implications?

- Elevated high-sensitivity C-reactive protein has been established as a reliable predictor of the risk of heart failure hospitalization, regardless of the different heart failure status and the severity of coronary stenosis at baseline.

Nonstandard Abbreviations and Acronyms

FIB-4	fibrosis 4
HFpEF	heart failure with preserved ejection fraction
MAFLD	metabolic dysfunction-associated fatty liver disease

Metabolic dysfunction-associated fatty liver disease (MAFLD), formerly named non-alcoholic fatty liver disease, is a highly prevalent metabolic liver condition worldwide, affecting up to ≈30% of the general adult population.^{1–5} Recent cohort studies suggested that patients with MAFLD have an increased risk of new-onset heart failure (HF), especially HF with preserved ejection fraction (HFpEF).^{6–8} A comprehensive meta-analysis of 11 longitudinal cohort studies (including ≈11.2 million middle-aged individuals from different countries) showed that MAFLD was associated with a 1.5-fold increased risk of new-onset HF over a median of 10 years.⁹

Despite a normal left ventricular ejection fraction (LVEF), HFpEF is a common chronic cardiac condition globally, where metabolic dysfunction (eg, obesity and type 2 diabetes) and low-grade chronic inflammation may contribute to its pathogenesis.^{10–12} HFpEF is associated with a substantially higher risk of adverse cardiovascular events and all-cause mortality.^{10–12}

Empiric evidence suggests that the unifying link between MAFLD and HFpEF is low-grade chronic inflammation, which may adversely affect cardiomyocyte function.^{13–16} This low-grade inflammatory state is characterized by increased biomarkers in the bloodstream.^{17,18} For example, hs-CRP (high-sensitivity C-reactive protein) is one of the most widely used

biomarkers for systemic inflammation, and an increase in hs-CRP is predictive of adverse cardiovascular events, such as myocardial infarction, stroke, and HF.^{19–21} However, to our knowledge, the ability of serum hs-CRP level to predict future HF events in patients with MAFLD and preserved LVEF has not been extensively explored.

The main aims of our longitudinal study were as follows: (1) to examine the prevalence of HFpEF among patients with MAFLD and suspected coronary artery disease (CAD) undergoing elective coronary angiography; and (2) to evaluate the associations between increased serum hs-CRP levels and the future risk of HF hospitalizations in this patient population.

METHODS

Study Design

This retrospective longitudinal study enrolled individuals diagnosed with MAFLD and suspected CAD who had undergone conventional echocardiograms at the First Affiliated Hospital of Wenzhou Medical University between January 2009 and February 2023. The inclusion criteria were as follows: (1) aged 18 years or older, (2) diagnosis of MAFLD, (3) presence of LVEF ≥50% on conventional echocardiography, and (4) acceptance to undergo an elective coronary angiography. Patients who did not meet the inclusion criteria, patients who had had any acute inflammatory condition and any other organ failure, rheumatological disorder, or malignancy, or those lost at follow-up were excluded from the study (as specified in [Figure S1](#)).

Baseline data for all patients were collected retrospectively through electronic medical records, which provided various details such as medical history, demographic variables, clinical and laboratory data, use of medications, liver ultrasound results, echocardiography evaluation findings, and subsequent follow-up data.

The study was conducted in compliance with the Declaration of Helsinki, and the ethics committee of the First Affiliated Hospital of Wenzhou Medical University approved the study protocol with a waiver for informed consent due to the infeasibility of obtaining informed consent, given the study's retrospective design. The data that support the findings of this study are available from the first author (zhouxiaodong@wmu.edu.cn) upon reasonable request.

Diagnosis of MAFLD

In all patients, MAFLD was diagnosed by the presence of hepatic steatosis on liver ultrasound or blood biomarkers/scores in combination with at least 1 of the following metabolic risk factors: overweight/obesity, type 2 diabetes, or at least 2 of the

following metabolic abnormalities: (1) waist circumference $\geq 90/80$ cm in men and women; (2) blood pressure $\geq 130/85$ mmHg or specific drug treatment; (3) serum triglycerides ≥ 150 mg/dL (≥ 1.70 mmol/L) or specific drug treatment; (4) serum high-density lipoprotein-cholesterol < 40 mg/dL (< 1.0 mmol/L) for men and < 50 mg/dL (< 1.3 mmol/L) for women or specific drug treatment; (5) prediabetes, defined as fasting glucose levels between 100 and 125 mg/dL (5.6 to 6.9 mmol/L), or glycated hemoglobin levels ranging from 5.7% to 6.4% (39 to 47 mmol/mol); (6) a Homeostasis Model Assessment score for insulin resistance ≥ 2.5 ; and (7) a serum hs-CRP level > 2 mg/L.^{22,23} Fibrosis 4 (FIB-4) index was calculated as follows: age \times aspartate aminotransferase (U/L)/[platelet (10^9 /L) \times alanine aminotransferase $^{1/2}$ (U/L)].²⁴ Serum hs-CRP was measured using an immunoturbidimetry assay on a Beckman Coulter analyzer (AU5800).

Baseline HF Status

The study population was subdivided into the non-HF, pre-HFpEF, and HFpEF groups according to the presence or absence of HF symptoms and impaired cardiac function at baseline. The diagnosis of pre-HFpEF was defined as asymptomatic patients (absence of signs or symptoms of HF) with “preserved” ejection fraction (LVEF $\geq 50\%$) who had at least 1 of the following conditions: evidence of structural heart disease (including left atrial enlargement), diastolic dysfunction, presence of multiple cardiovascular risk factors with elevated levels of natriuretic peptides, or persistently elevated cardiac troponins, in the absence of competing diagnoses.^{25,26} The diagnosis of HFpEF was defined as symptomatic patients with “preserved” ejection fraction (LVEF $\geq 50\%$) who had at least 1 of the following conditions: evidence of structural heart disease (including left atrial enlargement) diastolic dysfunction, multiple cardiovascular risk factors with elevated levels of serum natriuretic peptides, or persistently elevated cardiac troponins, in the absence of competing diagnoses.^{25,26} In contrast to “true HFpEF,” the key clinical component of pre-HFpEF was the absence of HF signs and symptoms.

Coronary Angiography

All patients underwent elective coronary angiography to quantify the presence of CAD. The reports of coronary angiographies of all patients were meticulously reviewed and categorized in cooperation with the study’s cardiologist, X-D Zhou. Mild CAD was defined as coronary stenoses $< 50\%$, moderate CAD as stenoses 50% to 70%, and severe CAD as having at least 1 proximal coronary artery with $> 70\%$ stenosis based on angiography.²⁷

Study Outcomes

Clinical follow-up data were collected from inpatient and outpatient medical records to analyze the clinical study outcome. The length of the follow-up was determined as the time between the MAFLD diagnosis and the first occurrence of either the end of clinical follow-up or the time-to-event end points, whichever came first. Patients were followed until April 2023 to examine the primary clinical outcome for predictive purposes systematically. The study outcome was time to the first hospitalization for HF.

Statistical Analysis

All statistical analyses were performed using IBM SPSS software, version 23.0 for Windows. Continuous variables were expressed as means \pm SD or medians (interquartile ranges [IQRs]), and categorical variables as percentages. Statistical comparisons between the study groups were carried out using the unpaired Student’s *t* test (for normally distributed continuous variables), the Mann–Whitney *U* test (for nonnormally distributed continuous variables), and the chi-square test (for categorical variables). We performed unadjusted and adjusted Cox proportional hazards models to examine the association between serum hs-CRP levels (stratified by increasing quartiles from Q1 to Q4) and the risk of HF hospitalization during the follow-up. The Cox proportional hazards models provided the hazard ratios (HR) and 95% CIs. Furthermore, a Kaplan–Meier survival analysis was also performed to calculate the event-free survival curves, and the log-rank test was used to test the presence of any significant differences between the curves. A *P* value < 0.05 was considered statistically significant.

RESULTS

Baseline Characteristics

The final sample for analysis consisted of 10 019 middle-aged Chinese patients (mean age, 63.3 \pm 10.6 years; 38.5% women) with MAFLD and suspected CAD who underwent elective coronary angiography, after excluding those who did not meet the study’s inclusion criteria (Figure S1). At baseline, 3133 (31.3%) patients had non-HF, 3427 (34.2%) had pre-HFpEF, and 3459 (34.5%) had HFpEF, respectively. Detailed baseline characteristics, traditional cardiovascular risk factors, and laboratory parameters of patients stratified by different baseline HF statuses are shown in Table 1. Patients with HFpEF were older, had more comorbidities, a more atherogenic risk profile, a greater prevalence of severe coronary stenosis, larger left ventricular end-diastolic diameter, higher FIB-4 score, and lower hepatic steatosis index score compared with the other 2 patient groups. Serum hs-CRP levels both in the

Table 1. Baseline Clinical and Biochemical Characteristics of Patients With MAFLD and Suspected Coronary Artery Disease Stratified by Baseline Heart Failure Status

	All	Non-HF	Pre-HFpEF	HFpEF	P value
Subjects, n	10019	3133	3427	3459	
Age, y	63.3±10.6	60.0±9.6	63.9±10.7	65.8±10.7	<0.001
Male sex, n (%)	6162 (61.5%)	2017 (64.4%)	2048 (59.8%)	2097 (60.6%)	<0.001
Body mass index, kg/m ²	26.4±3.1	26.3±2.8	26.4±3.1	26.6±3.3	0.014
Current smokers, n (%)	4182 (41.7%)	1304 (41.6%)	1452 (42.4%)	1426 (41.2%)	0.621
Current drinking, n (%)	3270 (32.6%)	1065 (34%)	1112 (32.4%)	1093 (31.6%)	0.114
Follow-up period, y	3.2 (0.9–5.9)	3.4 (1.2–5.9)	3.2 (1.0–6.0)	2.8 (0.7–5.7)	0.084
Comorbidities, n (%)					
Hypertension	7790 (77.8%)	2328 (74.3%)	2720 (79.4%)	2742 (79.3%)	<0.001
Diabetes	4252 (42.4%)	1148 (36.6%)	1523 (44.4%)	1581 (45.7%)	<0.001
Dyslipidemia	6620 (66.1%)	2176 (69.5%)	2282 (66.6%)	2162 (62.5%)	<0.001
Atrial fibrillation	964 (9.6%)	175 (5.6%)	377 (11.0%)	412 (11.9%)	<0.001
Previous stroke	972 (9.7%)	237 (7.6%)	336 (9.8%)	399 (11.5%)	<0.001
Previous myocardial infarction	1828 (18.2%)	138 (4.4%)	834 (24.3%)	856 (24.7%)	<0.001
Chronic kidney disease	993 (9.9%)	130 (4.1%)	395 (11.5%)	468 (13.5%)	<0.001
Medications at admission, n (%)					
Loop diuretics	1838 (18.3%)	149 (4.8%)	715 (20.9%)	974 (28.2%)	<0.001
Spirolactone	1399 (14.0%)	143 (4.6%)	480 (14.0%)	776 (22.4%)	<0.001
Angiotensin-converting enzyme inhibitors/angiotensin II receptor blockers/angiotensin receptor neprilysin inhibitors	6303 (62.9%)	1761 (56.2%)	2239 (65.3%)	2303 (66.6%)	<0.001
Beta blockers	6580 (65.7%)	1805 (57.6%)	2352 (68.6%)	2423 (70.0%)	<0.001
Sodium-glucose cotransporter-2 inhibitors	116 (1.2%)	25 (0.8%)	48 (1.4%)	43 (1.2%)	0.063
MAFLD-related scores					
Fibrosis-4 index	1.9±2.4	1.5±2.5	2.0±2.2	2.1±2.5	<0.001
Hepatic steatosis index	37.0±5.3	37.5±4.9	36.8±5.5	36.8±5.3	<0.001
Severity of coronary stenosis					<0.001
Mild CAD (<50%)	1916 (19.1%)	808 (25.8%)	516 (15.1%)	592 (17.1%)	
Medium CAD (50–70%)	4412 (44.0%)	1493 (47.7%)	1435 (41.9%)	1484 (42.9%)	
Severe CAD (>70%)	3691 (36.8%)	832 (26.6%)	1476 (43.1%)	1383 (40.0%)	
Echocardiographic parameters					
LV ejection fraction, %	65.3±6.9	67.0±6.0	65.0±7.1	64.1±7.2	<0.001
Left atrial diameter, cm	41.6±6.7	40.5±5.2	41.9±6.9	42.5±7.4	<0.001
LV diastolic dysfunction, cm	48.6±7.0	48.4±5.7	48.5±7.4	49.0±7.7	0.002
LV systolic dimension, cm	30.8±5.8	30.3±4.6	30.8±5.9	31.3±6.5	<0.001
Pulmonary arterial pressure, mmHg	29.3±8.0	27.7±6.3	29.4±8.1	30.5±9.1	<0.001
Laboratory values					
High-sensitivity C-reactive protein, mg/L	3.4 (1.6–8.3)	2.7 (1.1–5.0)	4.5 (1.9–10.0)	5.0 (2.1–10.1)	<0.001
Quartile 1 (≤3.26)	2549 (25.4%)	1123 (35.8%)	747 (21.8%)	679 (19.6%)	<0.001
Quartile 2 (3.26–7.00)	2463 (24.6%)	954 (30.5%)	779 (22.7%)	730 (21.1%)	
Quartile 3 (7.01–36.9)	2515 (25.1%)	622 (19.9%)	914 (26.7%)	979 (28.3%)	
Quartile 4 (>36.9)	2492 (24.9%)	434 (13.9%)	987 (28.8%)	1071 (31.0%)	
N-terminal pro-B-type natriuretic peptide, ng/L	146.0 (56.4–557.0)	46.1 (26.0–74.0)	189.0 (76.2–638.0)	334.0 (128.0–1276.0)	<0.001
High-sensitivity cardiac troponin I, µg/L	0.0 (0.0–7.0)	0.0 (0.0–0.0)	0.0 (0.0–5.2)	3.0 (0.0–12.5)	<0.001

(Continued)

Table 1. Continued

	All	Non-HF	Pre-HFpEF	HFpEF	P value
Estimated glomerular filtration rate, mL/min \times 1.73m ²	90.5 (73.95–102.2)	96.4 (84.2–106.8)	87.9 (70.9–100.1)	85.8 (66.2–98.5)	<0.001
Platelet count, 10 ⁹ /L	220 \pm 67	224 \pm 62	219 \pm 70	216 \pm 67	<0.001
Alanine aminotransferase/aspartate aminotransferase ratio	1.11 \pm 0.47	1.20 \pm 0.45	1.07 \pm 0.44	1.06 \pm 0.49	<0.001
Albumin, g/dL	40.4 \pm 8.5	41.7 \pm 8.4	39.8 \pm 9.3	39.8 \pm 7.8	<0.001
Glycated hemoglobin, %	7.0 \pm 2.2	6.7 \pm 1.4	7.0 \pm 1.6	7.1 \pm 3.1	<0.001

Data are expressed as means \pm SD, medians (interquartile ranges, IQR), or percentages. CAD indicates coronary artery disease; HF, heart failure; HFpEF, heart failure with preserved ejection fraction; LV, left ventricular; MAFLD, metabolic dysfunction-associated fatty liver disease.

pre-HFpEF group (4.5 mg/L; IQR, 1.9–10 mg/L) and in the HFpEF group (5.0 mg/L; IQR, 2.1–10.1 mg/L) were significantly higher than those in the non-HF group (2.7 mg/L; IQR, 1.1–5.0 mg/L).

Pre-HFpEF and HFpEF Prevalence and Incident HF Hospitalization

As shown in Figure 1, about two-thirds of patients had pre-HFpEF or HFpEF, and the prevalence rates of these 2 cardiac conditions increased across quartiles of serum hs-CRP at baseline. During a median follow-up period of 3.2 years (IQR, 0.9–5.9 years), hospitalizations for HF occurred in 1942 (19.4%) patients, with an incidence rate of 6.1 events per 100 person-years. As

also shown in the Figure 1C, patients with HFpEF or pre-HFpEF at baseline were more likely to be hospitalized for HF than those in the non-HF group.

Hs-CRP and Risk of Incident HF Hospitalization

As shown in Table 2, patients in the highest baseline quartile of hs-CRP levels had a markedly higher risk of HF hospitalization compared with those in the lowest hs-CRP quartile (unadjusted HR, 6.937 [95% CI, 5.857–8.215]). Increased serum hs-CRP levels were significantly associated with a higher risk of HF hospitalization (adjusted HR, 4.421 [95% CI, 3.720–5.254]), even after adjustment for age, sex, smoking




Figure 1. Prevalence rates of different categories of HF (ie, non-HF, preHFpEF, and HFpEF) in the whole cohort of patients with MAFLD (A) and in patients with MAFLD stratified by serum hs-CRP quartiles (Q1 to Q4) (B). Incidence rates of hospitalization for HF according to different categories of HF at baseline (C).

HF indicates heart failure; HFpEF, heart failure with preserved ejection fraction; hs-CRP, high-sensitivity C-reactive protein; and MAFLD, metabolic dysfunction-associated fatty liver disease.

Table 2. Associations Between hs-CRP Concentration Quartiles and the Risk of Heart Failure Hospitalization in Patients With Different Heart Failure Status at Baseline

Groups	hs-CRP quartile	Events, n (%)	Events/100 person-years	Model 1 Hazard ratio (95% CI)	P value	Model 2 Hazard ratio (95% CI)	P value	Model 3 Hazard ratio (95% CI)	P value
All subjects	Q1 (N=2506)	154 (6.1%)	1.7	Ref.		Ref.		Ref.	
	Q2 (N=2520)	249 (9.9%)	2.6	1.546 (1.265–1.891)	<0.001	1.488 (1.217–1.820)	<0.001	1.487 (1.216–1.818)	<0.001
	Q3 (N=2493)	492 (19.7%)	5.0	2.966 (2.475–3.554)	<0.001	2.591 (2.161–3.108)	<0.001	2.411 (2.010–2.893)	<0.001
	Q4 (N=2500)	1047 (41.9%)	11.8	6.937 (5.857–8.215)	<0.001	5.544 (4.672–6.579)	<0.001	4.421 (3.720–5.254)	<0.001
Non-HF	Q1 (N=1244)	8 (0.6%)	0.2	Ref.		Ref.		Ref.	
	Q2 (N=872)	14 (1.6%)	0.4	2.22 (0.931–5.291)	0.072	2.203 (0.924–5.253)	0.075	2.110 (0.883–5.040)	0.093
	Q3 (N=601)	26 (4.3%)	1.0	5.426 (2.456–11.988)	<0.001	5.351 (2.419–11.836)	<0.001	4.910 (2.216–10.883)	<0.001
	Q4 (N=416)	69 (16.6%)	4.0	21.697 (10.434–45.117)	<0.001	20.888 (9.978–43.726)	<0.001	18.065 (8.589–37.998)	<0.001
Pre-HFpEF	Q1 (N=655)	62 (9.5%)	2.6	Ref.		Ref.		Ref.	
	Q2 (N=833)	86 (10.3%)	2.7	1.047 (0.755–1.451)	0.783	1.091 (0.787–1.512)	0.603	1.171 (0.843–1.625)	0.346
	Q3 (N=954)	186 (19.5%)	4.8	1.911 (1.433–2.547)	<0.001	1.777 (1.332–2.370)	<0.001	1.734 (1.298–2.317)	<0.001
	Q4 (N=985)	380 (38.6%)	10.3	4.083 (3.121–5.341)	<0.001	3.663 (2.797–4.798)	<0.001	3.179 (2.420–4.175)	<0.001
HFpEF	Q1 (N=607)	84 (13.8%)	3.6	Ref.		Ref.		Ref.	
	Q2 (N=815)	123 (18.3%)	5.1	1.389 (1.063–1.815)	0.016	1.364 (1.044–1.783)	0.023	1.373 (1.050–1.795)	0.021
	Q3 (N=938)	369 (29.9%)	8.4	2.328 (1.824–2.972)	<0.001	2.170 (1.699–2.772)	<0.001	2.120 (1.658–2.712)	<0.001
	Q4 (N=1099)	598 (54.4%)	17.1	4.698 (3.737–5.905)	<0.001	4.108 (3.262–5.174)	<0.001	3.502 (2.776–4.417)	<0.001

Serum hs-CRP quartiles were defined as follows: Q1: ≤ 3.26 mg/L; Q2: 3.26–7.00 mg/L; Q3: 7.01–36.9 mg/L; and Q4: > 36.9 mg/L. Cox regression Model 1: unadjusted; Cox regression Model 2: adjusted for age and sex; Cox regression Model 3: further adjusted for smoking, alcohol intake, body mass index, hypertension, diabetes, dyslipidemia, atrial fibrillation, previous stroke, previous myocardial infarction, chronic kidney disease, and current use of loop diuretics, spironolactone, angiotensin-converting enzyme inhibitors/angiotensin II receptor blockers/angiotensin receptor neprilysin inhibitors, or beta blockers. HF indicates heart failure; HFpEF, heart failure with preserved ejection fraction; and hs-CRP, high-sensitivity C-reactive protein.

history, alcohol intake, body mass index, hypertension, diabetes, dyslipidemia, atrial fibrillation, previous stroke, previous myocardial infarction, chronic kidney disease, and current use of loop diuretics, spironolactone, angiotensin-converting enzyme inhibitors/angiotensin II receptor blockers/angiotensin receptor neprilysin inhibitors, or beta blockers. A Kaplan–Meier survival analysis showed a significant incremental increase in the risk of HF hospitalization across serum hs-CRP quartiles ($P < 0.001$ by the log-rank test, [Figure 2](#)).

Hs-CRP and Increased Risk of HF Hospitalization in Subgroups

We performed subgroup analyses to examine the significant associations between serum hs-CRP quartiles and the risk of HF hospitalization. This risk remained

statistically significant even after adjusting for potential confounders, that is, regardless of the HF status ([Table 2](#) and [Figure 3](#)), the severity of coronary stenoses ([Table S1](#) and [Figure 3](#)), or FIB-4 score at baseline ([Table S2](#) and [Figure 4](#)).

DISCUSSION

The key findings from this analysis are summarized as follows: (1) pre-HFpEF and HFpEF are 2 highly prevalent cardiac conditions affecting up to nearly two-thirds of this patient population with MAFLD and suspected CAD; (2) patients with pre-HFpEF or HFpEF are at higher risk of being hospitalized for HF than those in the non-HF group, with incidence rates of 3.7% in non-HF, 20.8% in pre-HFpEF, and 32.1% in HFpEF, respectively; (3) serum hs-CRP levels are increased in




Figure 2. Kaplan–Meier event-free survival curve of the risk for HF hospitalization in the whole cohort of patients stratified by serum hs-CRP quartiles.

P values were tested by log-rank test. Under the x-axis are reported the number of subjects in each serum hs-CRP quartile at each time. HF indicates heart failure; and hs-CRP, high-sensitivity C-reactive protein.

patients with pre-HFpEF or HFpEF; and (4) increased hs-CRP levels predict the future risk of hospitalization for HF, regardless of the different HF status and the severity of coronary stenosis at baseline.

Although serum hs-CRP levels are closely associated with an elevated risk of adverse cardiac events in individuals with cardiometabolic disease, limited data specifically evaluated the possible connections between serum hs-CRP levels and HFpEF in patients with MAFLD. Our study provides new insights about this question from a large cohort of middle-aged Chinese patients with MAFLD and suspected CAD.

Prevalence of HFpEF in MAFLD

Patients with MAFLD often have multiple cardiometabolic disorders leading to myocardial remodeling and diastolic dysfunction over time.^{7,28,29} However, these individuals are more likely to develop HFpEF than HF with reduced LVEF.^{30,31} Hence, understanding the prevalence of pre-HFpEF and HFpEF among patients with MAFLD is clinically important for promptly identifying individuals at higher risk of developing HFpEF and

who may benefit from targeted pharmacotherapies to reduce their HF risk.

In the present large study, a significant proportion of our individuals with MAFLD and normal LVEF had pre-HFpEF or HFpEF (about 34% for every condition). Moreover, the overall rates of HF hospitalization we observed in our study were nearly 5 to 8 times greater in the groups with pre-HFpEF and HFpEF than in the non-HF group, with rates of 20.8% in pre-HFpEF versus 32.1% in HFpEF versus 3.7% in non-HF, respectively.

Chronic Inflammation May Link MAFLD to HFpEF

Low-grade chronic inflammation is a common mechanism that may pathophysiologically link MAFLD to the development and progression of HFpEF.^{13,32,33} MAFLD, especially in its more advanced histological forms (ie, metabolic steatohepatitis and advanced fibrosis), may exert adverse effects mainly through the systemic release of multiple proinflammatory, prooxidant, and profibrotic mediators, thus contributing to the development of various extrahepatic complications, including




Figure 3. HRs and 95% CIs for HF hospitalization in patients stratified by different status of HF and severity of coronary stenosis at baseline: **A**, Non-HF; **B**, Pre-HFpEF; **C**, HFpEF; **D**, Mild stenosis; **E**, Moderate stenosis; and **F**, Severe stenosis. HF indicates heart failure; HFpEF, heart failure with preserved ejection fraction; HR, hazard ratio; and hs-CRP, high-sensitivity C-reactive protein.

functional and structural cardiac abnormalities that can lead to new-onset HFpEF.^{34–37}

Hs-CRP Levels, Pre-HFpEF or HFpEF and the Future Risks of HF Hospitalization

The findings of our study highlight the importance of measuring serum hs-CRP levels in patients with MAFLD and suspected CAD and represent an essential consideration for hepatologists when assessing the future risk of HF hospitalization in this patient population. Hepatologists may overlook hs-CRP measurements

when MAFLD presents with preserved LVEF and no apparent signs and symptoms of HF.

In our study, we found that compared with those with the lowest serum hs-CRP levels, patients with increased hs-CRP levels not only had significantly higher prevalence rates of pre-HFpEF and HFpEF but also had higher incidence rates of HF hospitalization over a mean period of 3.2 years, irrespective of the severity of coronary stenosis or different HF status at baseline. Thus, serum hs-CRP may be a reliable biomarker for predicting the future risk of HF hospitalization in patients with MAFLD. The present findings also suggest




Figure 4. HRs and 95% CIs for HF hospitalization in patients stratified by MAFLD-related scores: **(A)** FIB-4<1.3; **(B)** FIB-4 between 1.3 and 2.67; **(C)** FIB-4≥2.67. FIB-4 indicates fibrosis 4; HF, heart failure; HR, hazard ratio; hs-CRP, high-sensitivity C-reactive protein; and MAFLD, metabolic dysfunction-associated fatty liver disease.

Downloaded from <http://ahajournals.org> by on January 22, 2024

that hepatologists need to pay greater attention to the potential risk of HF in patients with MAFLD and normal LVEF.

Limitations

The current study has some important limitations. First, we conducted the research retrospectively at a single academic center, which may have resulted in selection bias. Second, we acknowledge that the study patients referred for elective coronary angiography may have experienced referral bias, leading to an increased risk of having HF among people suspected of CAD. Third, the length of follow-up was relatively short. Fourth, the primary outcome of the study was to investigate the first hospitalization for HF, and other clinical outcomes, such as acute myocardial infarction, stroke, and all-cause and cause-specific mortality rates, were not considered. Finally, we also recognize that using electronic medical records may have led to underestimating HF hospitalization rates because these electronic records may not have captured instances where patients were admitted to hospitals outside our institution.

CONCLUSIONS

Among Chinese middle-aged individuals with MAFLD and suspected CAD undergoing elective coronary angiography, there was a high prevalence of baseline pre-HFpEF and HFpEF. Furthermore, there was an increased risk of HF hospitalization in those with elevated serum hs-CRP levels.

ARTICLE INFORMATION

Received October 6, 2023; accepted December 18, 2023.

Affiliations

Department of Cardiovascular Medicine, The Heart Center (X.-D.Z.) and Medical Care Center (Q.-F.C.), The First Affiliated Hospital of Wenzhou Medical University, Wenzhou, China; Institute of Aging, Key Laboratory of Alzheimer's Disease of Zhejiang Province, Wenzhou Medical University, Wenzhou, China (Q.-F.C.); Department of Medicine, University of Verona, Italy (G.T.); Metabolic Diseases Research Unit, IRCCS Sacro Cuore-Don Calabria Hospital, Negrar di Valpolicella (VR), Italy (G.T.); Southampton National Institute for Health and Care Research Biomedical Research Centre, University Hospital Southampton, and University of Southampton, Southampton General Hospital, Southampton, United Kingdom (C.D.B.); Center for Prevention of Cardiovascular Disease, Section on Cardiovascular Medicine, Wake Forest University School of Medicine, Winston-Salem, NC (M.D.S.); MAFLD Research Center, Department of Hepatology, The First Affiliated Hospital of Wenzhou Medical University, Wenzhou, China (N.T., T.X., M.-H.Z.); Department of Internal Medicine, Division of Cardiology, Kangbuk Samsung Hospital, Sungkyunkwan University School of Medicine, Seoul, Korea (K.-C.S.); Liverpool Centre for Cardiovascular Science at University of Liverpool, Liverpool John Moores University and Liverpool Heart & Chest Hospital, Liverpool, United Kingdom (G.Y.L.); Danish Center for Health Services Research, Department of Clinical Medicine, Aalborg University, Aalborg, Denmark (G.Y.L.); Institute of Hepatology, Wenzhou Medical University, Wenzhou, China (M.-H.Z.); and Key Laboratory of Diagnosis and Treatment for the Development of Chronic Liver Disease in Zhejiang Province, Wenzhou, China (M.-H.Z.).

Acknowledgments

Xiao-Dong Zhou: Conceptualization, formal analysis, investigation, data curation, writing—original draft, visualization. Qin-Fen Chen: Conceptualization, formal analysis, investigation, data curation, writing—original draft, visualization. Giovanni Targher: Writing, investigation and reviewing. Christopher D. Byrne: Writing, investigation and reviewing. Michael D. Shapiro: Investigation. Na Tian: Investigation. Ki-Chul Sung: Investigation. Gregory Y. H. Lip: Investigation. Ming-Hua Zheng: Conceptualization, investigation, supervision, project administration, funding acquisition, writing—review and editing.

Sources of Funding

This paper was funded by grants from the National Natural Science Foundation of China (82070588, 82370577), High Level Creative Talents from Department of Public Health in Zhejiang Province (S2032102600032) and Project of New Century 551 Talent Nurturing in Wenzhou. Dr Targher is supported in part by grants from the School of Medicine, University of Verona, Verona, Italy. C.D.B. is supported in part by the Southampton National Institute for Health and Care Research Biomedical Research Centre (NIHR203319), UK.

Disclosures

Dr Lip is a consultant and speaker for BMS/Pfizer, Boehringer Ingelheim, Daiichi-Sankyo, Anthos. No fees are received personally. He is a National Institute for Health and Care Research Senior Investigator and co-principal investigator of the AFFIRMO project on multimorbidity in atrial fibrillation, which has received funding from the European Union's Horizon 2020 research and innovation program under grant agreement No 899871. The remaining authors have no disclosures to report.

Supplemental Material

Tables S1–S2

Figure S1

REFERENCES

- Feng G, Valenti L, Wong V, Fouad Y, Yilmaz Y, Kim W, Sebastiani G, Younossi ZM, Hernandez-Gea V, Zheng MH. Re-compensation in cirrhosis: unraveling the evolving natural history of nonalcoholic fatty liver disease. *Nat Rev Gastroenterol Hepatol*. 2023; in press. doi: [10.1038/s41575-023-00846-4](https://doi.org/10.1038/s41575-023-00846-4)
- Younossi Z, Koenig A, Abdelatif D, Fazel Y, Henry L, Wymer M. Global epidemiology of nonalcoholic fatty liver disease—meta-analytic assessment of prevalence, incidence, and outcomes. *Hepatology (Baltimore, Md)*. 2016;64:73–84. doi: [10.1002/hep.28431](https://doi.org/10.1002/hep.28431)
- Duell PB, Welty FK, Miller M, Chait A, Hammond G, Ahmad Z, Cohen DE, Horton JD, Pressman GS, Toth PP. Nonalcoholic fatty liver disease and cardiovascular risk: a scientific statement from the American Heart Association. *Arterioscler Thromb Vasc Biol*. 2022;42:e168–e185. doi: [10.1161/atv.0000000000000153](https://doi.org/10.1161/atv.0000000000000153)
- Lazarus J, Mark H, Anstee Q, Arab J, Batterham R, Castera L, Cortez-Pinto H, Crespo J, Cusi K, Dirac M, et al. Advancing the global public health agenda for NAFLD: a consensus statement. *Nat Rev Gastroenterol Hepatol*. 2022;19:60–78. doi: [10.1038/s41575-021-00523-4](https://doi.org/10.1038/s41575-021-00523-4)
- Li J, Zou B, Yeo YH, Feng Y, Xie X, Lee DH, Fujii H, Wu Y, Kam LY, Ji F, et al. Prevalence, incidence, and outcome of non-alcoholic fatty liver disease in Asia, 1999–2019: a systematic review and meta-analysis. *Lancet Gastroenterol Hepatol*. 2019;4:389–398. doi: [10.1016/s2468-1253\(19\)30039-1](https://doi.org/10.1016/s2468-1253(19)30039-1)
- Zhou XD, Cai J, Targher G, Byrne CD, Shapiro MD, Sung KC, Somers VK, Chahal CAA, George J, Chen LL, et al. Metabolic dysfunction-associated fatty liver disease and implications for cardiovascular risk and disease prevention. *Cardiovasc Diabetol*. 2022;21:270. doi: [10.1186/s12933-022-01697-0](https://doi.org/10.1186/s12933-022-01697-0)
- Packer M. Atrial fibrillation and heart failure with preserved ejection fraction in patients with nonalcoholic fatty liver disease. *Am J Med*. 2020;133:170–177. doi: [10.1016/j.amjmed.2019.09.002](https://doi.org/10.1016/j.amjmed.2019.09.002)
- Sun DQ, Targher G, Byrne CD, Wheeler DC, Wong VW, Fan JG, Tilg H, Yuan WJ, Wanner C, Gao X, et al. An international Delphi consensus statement on metabolic dysfunction-associated fatty liver disease and risk of chronic kidney disease. *Hepatobiliary Surg Nutr*. 2023;12:386–403. doi: [10.21037/hbsn-22-421](https://doi.org/10.21037/hbsn-22-421)

9. Mantovani A, Petracca G, Csermely A, Beatrice G, Bonapace S, Rossi A, Tilg H, Byrne C, Targher G. Non-alcoholic fatty liver disease and risk of new-onset heart failure: an updated meta-analysis of about 11 million individuals. *Gut*. 2022;72:372–380. doi: [10.1136/gutjnl-2022-327672](https://doi.org/10.1136/gutjnl-2022-327672)
10. Dunlay SM, Roger VL, Redfield MM. Epidemiology of heart failure with preserved ejection fraction. *Nat Rev Cardiol*. 2017;14:591–602. doi: [10.1038/nrcardio.2017.65](https://doi.org/10.1038/nrcardio.2017.65)
11. Sung K, Yoo T, Lee M, Byrne C, Zheng M, Targher G. Comparative associations of nonalcoholic fatty liver disease and metabolic dysfunction-associated fatty liver disease with coronary artery calcification: a cross-sectional and longitudinal cohort study. *Arterioscler Thromb Vasc Biol*. 2023;43:482–491. doi: [10.1161/atvbaha.122.318661](https://doi.org/10.1161/atvbaha.122.318661)
12. AbouEzzeddine OF, Kemp BJ, Borlaug BA, Mullan BP, Behfar A, Pislaru SV, Fudim M, Redfield MM, Chareonthaitawee P. Myocardial energetics in heart failure with preserved ejection fraction. *Circ Heart Fail*. 2019;12:e006240. doi: [10.1161/circheartfailure.119.006240](https://doi.org/10.1161/circheartfailure.119.006240)
13. Salah HM, Pandey A, Soloveva A, Abdelmalek MF, Diehl AM, Moylan CA, Wegermann K, Rao VN, Hernandez AF, Tedford RJ, et al. Relationship of nonalcoholic fatty liver disease and heart failure with preserved ejection fraction. *JACC Basic Transl Sci*. 2021;6:918–932. doi: [10.1016/j.jacbs.2021.07.010](https://doi.org/10.1016/j.jacbs.2021.07.010)
14. Wang A, Li Z, Sun Z, Wang Y, Fu S, Zhang D, Ma X. Heart failure with preserved ejection fraction and non-alcoholic fatty liver disease: new insights from bioinformatics. *ESC Heart Fail*. 2023;10:416–431. doi: [10.1002/ehf2.14211](https://doi.org/10.1002/ehf2.14211)
15. Salah HM, Pandey A, Van Spall HGC, Michos ED, McGarrah RW, Fudim M. Meta-analysis of nonalcoholic fatty liver disease and incident heart failure. *Am J Cardiol*. 2022;171:180–181. doi: [10.1016/j.amjcard.2022.02.012](https://doi.org/10.1016/j.amjcard.2022.02.012)
16. Minhas AMK, Bhopalwala HM, Dewaswala N, Salah HM, Khan MS, Shahid I, Biegus J, Lopes RD, Pandey A, Fudim M. Association of non-alcoholic fatty liver disease with in-hospital outcomes in primary heart failure hospitalizations with reduced or preserved ejection fraction. *Curr Probl Cardiol*. 2023;48:101199. doi: [10.1016/j.cpcardiol.2022.101199](https://doi.org/10.1016/j.cpcardiol.2022.101199)
17. Lawler PR, Bhatt DL, Godoy LC, Lüscher TF, Bonow RO, Verma S, Ridker PM. Targeting cardiovascular inflammation: next steps in clinical translation. *Eur Heart J*. 2021;42:113–131. doi: [10.1093/eurheartj/ehaa099](https://doi.org/10.1093/eurheartj/ehaa099)
18. Peters AE, Pandey A, Ayers C, Wegermann K, McGarrah RW, Grodin JL, Abdelmalek MF, Bekfani T, Blumer V, Diehl AM, et al. Association of liver fibrosis risk scores with clinical outcomes in patients with heart failure with preserved ejection fraction: findings from TOPCAT. *ESC Heart Fail*. 2021;8:842–848. doi: [10.1002/ehf2.13250](https://doi.org/10.1002/ehf2.13250)
19. Li Y, Zhong X, Cheng G, Zhao C, Zhang L, Hong Y, Wan Q, He R, Wang Z. Hs-CRP and all-cause, cardiovascular, and cancer mortality risk: a meta-analysis. *Atherosclerosis*. 2017;259:75–82. doi: [10.1016/j.atherosclerosis.2017.02.003](https://doi.org/10.1016/j.atherosclerosis.2017.02.003)
20. Gu HQ, Yang KX, Lin JX, Jing J, Zhao XQ, Wang YL, Liu LP, Meng X, Jiang Y, Li H, et al. Association between high-sensitivity C-reactive protein, functional disability, and stroke recurrence in patients with acute ischaemic stroke: a mediation analysis. *EBioMedicine*. 2022;80:104054. doi: [10.1016/j.ebiom.2022.104054](https://doi.org/10.1016/j.ebiom.2022.104054)
21. Lee M, Lee K, Kim DW, Cho JS, Kim TS, Kwon J, Kim CJ, Park CS, Kim HY, Yoo KD, et al. Relationship of serial high-sensitivity C-reactive protein changes to long-term clinical outcomes in stabilised patients after myocardial infarction. *Canadian J Cardiol*. 2022;38:92–101. doi: [10.1016/j.cjca.2021.10.007](https://doi.org/10.1016/j.cjca.2021.10.007)
22. Eslam M, Alkhoury N, Vajro P, Baumann U, Weiss R, Socha P, Marcus C, Lee WS, Kelly D, Porta G, et al. Defining paediatric metabolic (dysfunction)-associated fatty liver disease: an international expert consensus statement. *Lancet Gastroenterol Hepatol*. 2021;6:864–873. doi: [10.1016/s2468-1253\(21\)00183-7](https://doi.org/10.1016/s2468-1253(21)00183-7)
23. Eslam M, Newsome P, Sarin S, Anstee Q, Targher G, Romero-Gomez M, Zelber-Sagi S, Wai-Sun Wong V, Dufour J, Schattenberg J, et al. A new definition for metabolic dysfunction-associated fatty liver disease: an international expert consensus statement. *J Hepatol*. 2020;73:202–209. doi: [10.1016/j.jhep.2020.03.039](https://doi.org/10.1016/j.jhep.2020.03.039)
24. Kim BK, Kim DY, Park JY, Ahn SH, Chon CY, Kim JK, Paik YH, Lee KS, Park YN, Han KH. Validation of FIB-4 and comparison with other simple noninvasive indices for predicting liver fibrosis and cirrhosis in hepatitis B virus-infected patients. *Liver Int*. 2010;30:546–553. doi: [10.1111/j.1478-3231.2009.02192.x](https://doi.org/10.1111/j.1478-3231.2009.02192.x)
25. Ledwidge M, Dodd JD, Ryan F, Sweeney C, McDonald K, Fox R, Shorten E, Zhou S, Watson C, Gallagher J, et al. Effect of sacubitril/valsartan vs valsartan on left atrial volume in patients with pre-heart failure with preserved ejection fraction: the PARABLE randomized clinical trial. *JAMA Cardiol*. 2023;8:366–375. doi: [10.1001/jamacardio.2023.0065](https://doi.org/10.1001/jamacardio.2023.0065)
26. Bayes-Genis A, Pascual-Figal D, Núñez J. The pre-HFpEF stage: a new entity that requires proper phenotyping for better management. *Eur J Prev Cardiol*. 2021;28:935–936. doi: [10.1177/2047487320902326](https://doi.org/10.1177/2047487320902326)
27. Grundy SM, Stone NJ, Bailey AL, Beam C, Birtcher KK, Blumenthal RS, Braun LT, de Ferranti S, Faiella-Tommasino J, Forman DE, et al. 2018 AHA/ACC/AACVPR/AAPA/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA guideline on the management of blood cholesterol: a report of the American College of Cardiology/American Heart Association task force on clinical practice guidelines. *Circulation*. 2019;139:e1082–e1143. doi: [10.1161/cir.0000000000000625](https://doi.org/10.1161/cir.0000000000000625)
28. Zhou X, Targher G, Byrne C, Somers V, Kim S, Chahal C, Wong V, Cai J, Shapiro M, Eslam M, et al. An international multidisciplinary consensus statement on MAFLD and the risk of CVD. *Hepatol Int*. 2023;17:773–791. doi: [10.1007/s12072-023-10543-8](https://doi.org/10.1007/s12072-023-10543-8)
29. VanWagner LB, Wilcox JE, Colangelo LA, Lloyd-Jones DM, Carr JJ, Lima JA, Lewis CE, Rinella ME, Shah SJ. Association of nonalcoholic fatty liver disease with subclinical myocardial remodeling and dysfunction: a population-based study. *Hepatology (Baltimore, Md)*. 2015;62:773–783. doi: [10.1002/hep.27869](https://doi.org/10.1002/hep.27869)
30. Fudim M, Zhong L, Patel K, Khera R, Abdelmalek M, Diehl A, McGarrah R, Molinger J, Moylan C, Rao V, et al. Nonalcoholic fatty liver disease and risk of heart failure among Medicare beneficiaries. *J Am Heart Assoc*. 2021;10:e021654. doi: [10.1161/jaha.121.021654](https://doi.org/10.1161/jaha.121.021654)
31. Hage C, Löfgren L, Michopoulos F, Nilsson R, Davidsson P, Kumar C, Ekström M, Eriksson MJ, Lyngå P, Persson B, et al. Metabolomic profile in HFpEF vs HFrEF patients. *J Cardiac Fail*. 2020;26:1050–1059. doi: [10.1016/j.cardfail.2020.07.010](https://doi.org/10.1016/j.cardfail.2020.07.010)
32. Mantovani A, Byrne CD, Benfari G, Bonapace S, Simon TG, Targher G. Risk of heart failure in patients with nonalcoholic fatty liver disease: JACC review topic of the week. *J Am Coll Cardiol*. 2022;79:180–191. doi: [10.1016/j.jacc.2021.11.007](https://doi.org/10.1016/j.jacc.2021.11.007)
33. Lim GB. Neuromodulation reduces inflammation in HFpEF. *Nature Rev Cardiol*. 2022;19:147. doi: [10.1038/s41569-022-00672-2](https://doi.org/10.1038/s41569-022-00672-2)
34. Everett BM, Cornel JH, Lainscak M, Anker SD, Abbate A, Thuren T, Libby P, Glynn RJ, Ridker PM. Anti-inflammatory therapy with canakinumab for the prevention of hospitalization for heart failure. *Circulation*. 2019;139:1289–1299. doi: [10.1161/circulationaha.118.038010](https://doi.org/10.1161/circulationaha.118.038010)
35. Byrne C, Targher G. Non-alcoholic fatty liver disease-related risk of cardiovascular disease and other cardiac complications. *Diabetes Obes Metab*. 2022;24:28–43. doi: [10.1111/dom.14484](https://doi.org/10.1111/dom.14484)
36. Zhou Y, Zhou X, Wu S, Fan D, Van Poucke S, Chen Y, Fu S, Zheng M. Nonalcoholic fatty liver disease contributes to subclinical atherosclerosis: a systematic review and meta-analysis. *Hepatol Commun*. 2018;2:376–392. doi: [10.1002/hep4.1155](https://doi.org/10.1002/hep4.1155)
37. Franssen C, Chen S, Unger A, Korkmaz HI, De Keulenaer GW, Tschöpe C, Leite-Moreira AF, Musters R, Niessen HW, Linke WA, et al. Myocardial microvascular inflammatory endothelial activation in heart failure with preserved ejection fraction. *JACC Heart Fail*. 2016;4:312–324. doi: [10.1016/j.jchf.2015.10.007](https://doi.org/10.1016/j.jchf.2015.10.007)